Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Daniëlle van Lammeren"'
Autor:
Eva A. S. Koster, Peter A. von dem Borne, Peter van Balen, Erik W. A. Marijt, Jennifer M. L. Tjon, Tjeerd J. F. Snijders, Daniëlle van Lammeren, Hendrik Veelken, J. H. Frederik Falkenburg, Constantijn J. M. Halkes, Liesbeth C. de Wreede
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionUnmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can boost the beneficial Graft-versus-Leukemia (GvL) effect but may also induce severe Graft-versus-Host-Disease (GvHD). To improve the balan
Externí odkaz:
https://doaj.org/article/f91495ebee1a4669a0b7b64a4d0daa90
Autor:
Eva A. S. Koster, Edouard F. Bonneville, Peter A. von dem Borne, Peter van Balen, Erik W. A. Marijt, Jennifer M. L. Tjon, Tjeerd J. F. Snijders, Daniëlle van Lammeren, Hendrik Veelken, Hein Putter, J. H. Frederik Falkenburg, Constantijn J. M. Halkes, Liesbeth C. de Wreede
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Alloreactive donor-derived T-cells play a pivotal role in alloimmune responses after allogeneic hematopoietic stem cell transplantation (alloSCT); both in the relapse-preventing Graft-versus-Leukemia (GvL) effect and the potentially lethal complicati
Externí odkaz:
https://doaj.org/article/80d6d14acc53406c9e680ff7959ef80a
Autor:
Julia M Wortman, Emiel Leegwater, Daniëlle Van Lammeren-Venema, Cees Van Nieuwkoop, Annemieke Sobels, Erik B Wilms
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:1471-1475
Background and objectives Posaconazole is used as prophylaxis of invasive fungal disease in immune-compromised haematological patients with prolonged neutropenia after intensive chemotherapy. During routine therapeutic drug monitoring of posaconazole
Autor:
Eva A.S. Koster, Peter A. von dem Borne, Peter van Balen, Esther H.M. van Egmond, Erik W.A. Marijt, Sabrina A.J. Veld, Inge Jedema, Tjeerd J.F. Snijders, Daniëlle van Lammeren, Hendrik Veelken, J.H. Frederik Falkenburg, Liesbeth C. de Wreede, Constantijn J.M. Halkes
Publikováno v:
Transplantation and Cellular Therapy. 29:268.e1-268.e10
After allogeneic stem cell transplantation (alloSCT), patient-derived stem cells that survived the pre-transplant conditioning compete with engrafting donor stem cells for bone marrow (BM) repopulation. In addition, donor-derived alloreactive T-cells
Autor:
Hester F Lingsma, David van Klaveren, Arjan A van de Loosdrecht, Anna van Rhenen, Otto Visser, Valery E P P Lemmens, Nikki van Leeuwen, Gerwin Huls, Z L Rana Kaplan, Eduardus F M Posthuma, Danielle van Lammeren-Venema, Tjeerd J F Snijders, Catharina H M J van Elssen, Peter A von dem Borne, Nicole M A Blijlevens, Jan J Cornelissen, Marc H G P Raaijmakers, Avinash G Dinmohamed
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective Acute myeloid leukaemia (AML) prognosis is enhanced with intensive remission induction chemotherapy (ICT) in eligible patients. However, ICT eligibility perceptions may differ among healthcare professionals. This nationwide, population-base
Externí odkaz:
https://doaj.org/article/1ccfa978daa64b508cdfbda59b2174a6
Autor:
Jesse J. Swen, Michiel C. Verboom, Daniëlle van Lammeren, Sander Kouwen, Jeroen Diepstraten, Hans Gelderblom, Loes E. Visser, Erik B. Wilms, Ward F. Posthuma
Publikováno v:
Pharmacogenetics Genomics, 27(6), 223-226. Lippincott Williams & Wilkins
Pharmacogenetics and Genomics, 27(6), 223-226
Pharmacogenetics and Genomics, 27(6), 223-226
Imatinib trough levels have been associated with its clinical effects. During chronic use of imatinib, CYP2C8 becomes an important metabolizing enzyme because of cytochrome P450 3A4 (CYP3A4) autoinhibition. Single nucleotide polymorphisms (SNPs) in C
Autor:
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and
Externí odkaz:
https://doaj.org/article/71614de5d82b474e855269ada1ea2dee